Skip to main content

Table 2 HER2 co-amplification in breast cancer

From: HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors

Chr # Genes Band Start - end gene Median amplified percentage in HER2A (IQR) Median amplified percentage in non-HER2A (IQR)
3 1 3p25.1 MRPS25 4.2 1.1
3 5 3p24.1 KCNH8 - PP2D1 2.9 (0) 0.52 (0)
6 12 6q21 AIM1 - SNX3 7.5 (0.8) 2.6 (0.5)
10 10 10q22.3 ZMIZ1 - SFTPA1 6.5 (0.8) 1.7 (0.05)
11 34 11q12.3 NXF1 - PYGM 2.5 (0.4) 0.4 (0.06)
13 5 13q12.2-q12.3 FAM123A - SLC46A3 5.0 (0.4) 1.4 (0.3)
14 29 14q11.2 OR4K15 - RNASE1 4.2 (0.8) 0.7 (0.06)
14 15 14q11.2 OR5AU1 - OR4E2 3.4 (0.2) 0.6 (0.06)
17 55 17p11.2 LRRC48 - MTRNR2L1 5.0 (1.9) 1.5 (0.8)
17 419 17q11.1-q21.3 WSB1 - PPY 14.6 (12.3) 0.8 (0.7)
17 296 17q21.3-q24.3 NSF - MAP2K6 16.3 (7.3) 4.3 (1.7)
17 45 17q25.1 RPL38 - SAP30BP 9.2 (2.1) 2.9 (0.3)
20 3 20q13.2 ZFP64 - ZNF217 12.6 (0.8) 6.4 (0.6)
22 1 22q11.1 GAB4 2.5 0.3
  1. Genes that are significantly co-amplified with human epidermal growth factor receptor 2 (HER2) in The Cancer Genome Atlas (TCGA) and Metabric cohorts combined (Fisher’s exact false discovery rate (FDR) p value <0.05) (see Additional file 9E, Additional file 10). Median percentage of amplified genes (interquartile range, IQR) is shown per co-amplified region, in HER2 amplified (HER2A) and non-HER2A tumors